Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments
Lanshu Xiao, Yi Liu, Hui Chen, et al.
Cancer Biology & Therapy (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 24

Showing 24 citing articles:

Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications
Yuming Zhang, Lianhai Shan, Wentao Tang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 7, pp. 5185-5215
Closed Access | Times Cited: 14
Design, Synthesis and Biological Evaluation of Novel 9H Purine Derivatives as Potent CDK9 Inhibitors
Chunlei Tang, Dong Wang, Huabing Wang, et al.
Chemical Biology & Drug Design (2025) Vol. 105, Iss. 2
Closed Access | Times Cited: 1
Single-molecule live imaging of subunit interactions and exchange within cellular regulatory complexes
Thomas G.W. Graham, Claire Dugast‐Darzacq, Gina M. Dailey, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 7
Therapeutic targeting of BET bromodomain and other epigenetic acetylrecognition domain–containing factors
Sarah Gold, Ali Shilatifard
Current Opinion in Genetics & Development (2024) Vol. 86, pp. 102181-102181
Closed Access | Times Cited: 4
Structure-Guided Discovery of Novel N4-(Substituted Thiazol-2-yl)-N2-(4-Substituted phenyl)pyrimidine-2,4-Diamines as Potent CDK2 and CDK9 Dual Inhibitors with High Oral Bioavailability
Bei Zhang, Yanhong Li, Yukang Lin, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Identification of a Potent and Selective CDK9 Degrader as a Targeted Therapeutic Option for the Treatment of Small-Cell Lung Cancer
Yubo Wang, Mengmeng Wang, Ma Lan, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
CDK9 degradation Inhibits Gastroesophageal Cancer growth and Overcomes Radiation Resistance by Increasing Chromatin Accessibility and Downregulating YAP1/TEAD signaling
Yanting Zhang, Mikel Ghelfi, Xue Yu, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Drug design for cyclin-dependent kinase 9 (CDK9) inhibitors in silico
Kaori Asamitsu, Takatsugu Hirokawa, Takashi Okamoto
Biochemistry and Biophysics Reports (2025) Vol. 42, pp. 101988-101988
Closed Access
Cyclin-dependent kinases as mediators of aberrant transcription in prostate cancer
Razia Rahman, Luke A. Selth
Translational Oncology (2025) Vol. 55, pp. 102378-102378
Closed Access
Discovery of a Novel Dihydroisoquinolinone Derivative as a Potent CDK9 Inhibitor Capable of Overcoming L156F Mutant for the Treatment of Hematologic Malignancies
Chenliang Shi, Yun Wu, Fengming Zou, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Synthesis of 1,3,4-Thiadiazole Derivatives and Their Anticancer Evaluation
Camelia Elena Stecoza, George Mihai Nițulescu, Constantin Drǎghici, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 24, pp. 17476-17476
Open Access | Times Cited: 9
MC180295 is a highly potent and selective CDK9 inhibitor with preclinical in vitro and in vivo efficacy in cancer
Hanghang Zhang, Chen Huang, John Gordon, et al.
Clinical Epigenetics (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 3
CDK9 inhibitors for the treatment of solid tumors
Christiana Mo, Wei Ning, T. Li, et al.
Biochemical Pharmacology (2024) Vol. 229, pp. 116470-116470
Closed Access | Times Cited: 3
Advances in Cancer Therapy: A Comprehensive Review of CDK and EGFR Inhibitors
Mohammed Hawash
Cells (2024) Vol. 13, Iss. 19, pp. 1656-1656
Open Access | Times Cited: 3
CRBN‐PROTACs in Cancer Therapy: From Mechanistic Insights to Clinical Applications
Riya Thapa, Asif Ahmad Bhat, Gaurav Gupta, et al.
Chemical Biology & Drug Design (2024) Vol. 104, Iss. 5
Open Access | Times Cited: 3
Discovery of novel co-degradation CK1α and CDK7/9 PROTACs with p53 activation for treating acute myeloid leukemia
Kai Wang, Meixu Jiang, Huimin Liu, et al.
Bioorganic Chemistry (2024) Vol. 147, pp. 107319-107319
Closed Access | Times Cited: 2
Transcriptional regulation and therapeutic potential of cyclin-dependent kinase 9 (CDK9) in sarcoma
Robert L. Walker, Francis J. Hornicek, Zhenfeng Duan
Biochemical Pharmacology (2024) Vol. 226, pp. 116342-116342
Closed Access | Times Cited: 2
CDK9 targeting PROTAC L055 inhibits ERα-positive breast cancer
Wen‐Ming Chen, Yue Wu, Chuanyu Yang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 177, pp. 116972-116972
Open Access | Times Cited: 2
CDK9 Inhibition by Dinaciclib Is a Therapeutic Vulnerability in Epithelioid Hemangioendothelioma
Ajaybabu V. Pobbati, Ashley Burtscher, Nandini Rajaram Siva, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 18, pp. 4179-4189
Closed Access | Times Cited: 2
Selective inhibition of CDK9 in triple negative breast cancer
Ebtihal Mustafa, Geraldine Laven‐Law, Zoya Kikhtyak, et al.
Oncogene (2023) Vol. 43, Iss. 3, pp. 202-215
Open Access | Times Cited: 5
The signalling axis CDK12-BRCA1 mediates dinaciclib associated radiosensitivity through p53-mediated cellular senescence
Natalia Flores, Diego M. Fernández‐Aroca, Cristina Garnés‐García, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Using bioinformatics and artificial intelligence to map the cyclin-dependent kinase 4/6 inhibitor biomarker landscape in breast cancer
Kim Wager, Yao Wang, Andrew T. F. Liew, et al.
Future Oncology (2024), pp. 1-19
Open Access
BCL-2 inhibition in acute myeloid leukemia: resistance and combinations
Qi Zhang, Zhe Wang, Marina Konopleva
Expert Review of Hematology (2024), pp. 1-12
Closed Access
The CDK12–BRCA1 signaling axis mediates dinaciclib‐associated radiosensitivity through p53‐mediated cellular senescence
Natalia Flores, Diego M. Fernández‐Aroca, Cristina Garnés‐García, et al.
Molecular Oncology (2024)
Open Access
Page 1

Scroll to top